Last edition
News about "Tiziana Life Sciences "
Tiziana Doses Last Patient in Phase 2 Trial of Foralumab
Tiziana has dosed the last patient in its phase 2 trial of intranasal foralumab for mild Alzheimer’s, evaluating monotherapy and combinations with lecanemab or donanemab.
Tiziana Life Sciences | 19/10/2026 | By News Bureau | 104
Tiziana Submits Annual Safety Report for Intranasal Foralumab to FDA
Tiziana has submitted its annual safety report for intranasal foralumab to the US FDA, reporting an excellent safety profile based on 37.4 cumulative patient-years of exposure and highlighting the continued need for safer therapies following the FDA’s denial of Sanofi’s tolebrutinib for non-relapsing secondary progressive multiple sclerosis.
Tiziana Life Sciences | 30/12/2025 | By News Bureau | 338
Tiziana Life Sciences Signs Deal for Product Development Services with Renaissance Lakewood
Under this agreement, Renaissance will use its extensive expertise in pharmaceutical-nasal product development and manufacturing to support the production of intranasal foralumab, ensuring compliance with the highest quality and regulatory requirements.
Tiziana Life Sciences | 24/02/2025 | By Aishwarya | 252
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy